Hypera SA ADR HYPMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.45
- Day Range
- $5.47–5.58
- 52-Week Range
- $5.30–10.08
- Bid/Ask
- $5.39 / $5.62
- Market Cap
- $3.48 Bil
- Volume/Avg
- 5,533 / 11,386
Key Statistics
- Price/Earnings (Normalized)
- 10.05
- Price/Sales
- 2.19
- Dividend Yield (Trailing)
- 2.23%
- Dividend Yield (Forward)
- 2.23%
- Total Yield
- 2.52%
Company Profile
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and Non-Retail Market.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 10,301
- Website
- https://www.hypermarcas.com.br
Comparables
Valuation
|
Metric
|
HYPMY
|
PGMN3
|
KNSC11
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.05 | 48.20 | 8.65 |
Price/Book Value | 1.45 | 0.52 | 1.00 |
Price/Sales | 2.19 | 0.11 | 7.48 |
Price/Cash Flow | 11.15 | 4.20 | 9.66 |
Price/Earnings
HYPMY
PGMN3
KNSC11
Financial Strength
|
Metric
|
HYPMY
|
PGMN3
|
KNSC11
|
|---|---|---|---|
Quick Ratio | 1.22 | 0.37 | 10.00 |
Current Ratio | 1.74 | 1.39 | 10.00 |
Interest Coverage | 2.28 | 0.48 | — |
Quick Ratio
HYPMY
PGMN3
KNSC11
Profitability
|
Metric
|
HYPMY
|
PGMN3
|
KNSC11
|
|---|---|---|---|
Return on Assets (Normalized) | 7.38% | −0.16% | 10.61% |
Return on Equity (Normalized) | 15.83% | −0.58% | 11.76% |
Return on Invested Capital (Normalized) | 11.87% | 6.02% | 11.55% |
Return on Assets
HYPMY
PGMN3
KNSC11
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Nxzgpzrfq | Fyr | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Gzmkjxlnz | Wfqsgh | $68.1 Bil | |
HLN
| Haleon PLC ADR | Wpqmybprx | Brc | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Wfmvrkvw | Plhwx | $14.3 Bil | |
VTRS
| Viatris Inc | Tfrksbrs | Psj | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Fqfmfzsw | Krbr | $11.9 Bil | |
CTLT
| Catalent Inc | Sctgrhhv | Zgcyq | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Dfxsmyn | Ksddp | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Sbzbsvfm | Bzctp | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Gkvdfrkw | Sptftf | $3.4 Bil |